The pro- and anti-tumor role of ILC2s.

Details

Ressource 1Request a copy Under indefinite embargo.
UNIL restricted access
State: Public
Version: Final published version
License: Not specified
Serval ID
serval:BIB_ECAD6DCB8107
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
UNIL/CHUV
Title
The pro- and anti-tumor role of ILC2s.
Journal
Seminars in immunology
Author(s)
Trabanelli S. (co-first), Chevalier M.F. (co-first), Derré L. (co-last), Jandus C. (co-last)
ISSN
1096-3618 (Electronic)
ISSN-L
1044-5323
Publication state
Published
Issued date
02/2019
Peer-reviewed
Oui
Volume
41
Pages
101276
Language
english
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't ; Review
Publication Status: ppublish
Abstract
Group 2 innate lymphoid cells (ILC2s) are critical for the initiation of type 2 inflammatory diseases. However, ILC2s are also involved in the establishment of the immune microenvironment during tumor development, growth and metastasization. In this context, ILC2s have been shown to be either tumor-suppressive or tumor-promoting according to the tumor type, the cytokine secreted and the other immune cells that are, in turn, recruited and/or activated.
Keywords
Animals, Cytokines/metabolism, Disease Susceptibility, Humans, Immunity, Innate, Lymphocyte Subsets/immunology, Lymphocyte Subsets/metabolism, Lymphocytes/immunology, Lymphocytes/metabolism, Neoplasms/etiology, Neoplasms/metabolism, Neoplasms/pathology, Tumor Microenvironment/immunology, Cancer, Group-2 innate lymphoid cells, ILC2, Tumor immunoregulation
OAI-PMH
oai:serval.unil.ch:BIB_ECAD6DCB8107
DOI
10.1016/j.smim.2019.04.004
Pubmed
31130471
Web of science
000493792200010
Open Access
Yes
Create date
14/06/2019 16:24
Last modification date
30/07/2024 6:02
Usage data